Deals this week: Merck, Zydus Cadila Healthcare Limited, AbbVie

22nd September 2016 (Last Updated September 22nd, 2016 18:30)

Merck & Co and JenKem Technology have entered a distribution agreement to make Jenkem’s polyethylene glycol (PEG) products available for biomedical applications.

Merck & Co and JenKem Technology have entered a distribution agreement to make Jenkem’s polyethylene glycol (PEG) products available for biomedical applications.

Under the agreement, Merck will be responsible to market JenKem’s PEG product portfolio to the world market and make the products accessible to small volume PEG users.

The partnership enables Jenkem Technology to introduce its PEG products to the international market, as well as to biomedical researchers.

Zydus Cadila Healthcare and Takeda Pharmaceutical have entered a co-development agreement to develop a vaccine against Chikungunya.

"Zydus Cadila Healthcare and Takeda Pharmaceutical have entered a co-development agreement to develop a vaccine against Chikungunya."

Pursuant to the agreement, the two partners will jointly work on early stage research and development of the vaccine and will also be responsible for the commercialisation of the product.

AbbVie and BioArctic AB have entered an agreement to develop novel treatments for Parkinson’s disease and other chronic indications.

According to the agreement, the two partners will jointly develop BioArctic’s antibodies portfolio for the treatment of Parkinson’s and will also be responsible for the commercialisation of the products.

Aquinox Pharmaceuticals plans to raise $49.58m through the public offering of 5.3 million of its common stock shares.

Leerink Partners, Canaccord Genuity and Guggenheim Securities are acting as book runners and Cooley is acting as the legal advisor for the offering.

The company plans to invest the funds partly to advance the clinical development programme of AQX-1125 and partly to increase the working capital and for other general corporate purposes.

TenNor Therapeutics has raised gross proceeds of $25m in a series B venture financing round led by Northern Light Venture Capital and co-led by Frontline BioVentures, WuXi Venture Fund, Oriza Ventures and Relativity Healthcare Partners.

The company plans to invest the funds to conduct Phase III clinical trials of TNP-2092 and advance different clinical development programmes of its other products.